210
Participants
Start Date
June 22, 2017
Primary Completion Date
August 22, 2025
Study Completion Date
August 22, 2025
LN-145
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
LN-145 + pembrolizumab
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
Academisch Medisch Centrum, Amsterdam
Roswell Park Cancer Institute, Buffalo
Allegheny Health, Pittsburgh
UPMC Cancer Center, Pittsburgh
Istituto Europeo di Oncologia, Miano
University of Virginia, Charlottesville
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Madrid Sanchinarro, Madrid
Clínica Universidad de Navarra, Pamplona
University of Florida Health Cancer Center, Orlando
Sylvester Comprehensive Cancer Center, Miami
University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa
James Graham Brown Cancer Center, Louisville
The Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic, Cleveland
Karmanos Cancer Institute, Detroit
Medical College of Wisconsin, Milwaukee
Avera Medical Group Oncology, Sioux Falls
University of Chicago, Chicago
Centre Léon Bérard, Lyon
Centre Hospitalier Lyon Sud, Pierre-Bénite
LSU Health Sciences Center, New Orleans
University of Oklahoma Health Sciences Center, Oklahoma City
MD Anderson Cancer Center, Houston
St. Joseph's Hospital and Medical Center Center For Women's Health, Phoenix
University of Southern California, Los Angeles
Universitätsklinikum Erlangen, Erlangen
University of California San Diego, San Diego
Gustave Roussy Cancer Campus, Villejuif
Augusta University, Augusta
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Dana Farber Cancer Institute, Boston
Rutgers University, Newark
Universitätsklinikum Carl Gustav Carus, Dresden
Hospital Universitari Vall d'Hebrón, Barcelona
Institut Català d'Oncologia, Barcelona
Inselspital, Bern
Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie, Lausanne
Bristol Haematology and Oncology Centre, Bristol
Sarah Cannon Research Institute London, London
University College London Hospitals NHS Foundation Trust, London
NHS Greater Glasgow and Clyde, Glasgow
Guy's & St.Thomas NHS Foundation Trust, London
Lead Sponsor
Iovance Biotherapeutics, Inc.
INDUSTRY